Arkolith/Insider Trading/ETON/Form 4

Brynjelsen Sean

President & CEO, Director, 10% OwnerEton Pharmaceuticals, Inc. (ETON) · full profile →Form 4 · filed Jan 14, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 1, 2026Tax withholding(F)5K$15.39$77K2.9M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 12, 2026Grant(A)101K—$03.1M
Jan 12, 2026Grant(A)158K—$03.0M

Transaction Codes

F
Shares withheld for taxes
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-26-001290) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML